|
|
Post by cretin11 on Feb 22, 2020 12:30:37 GMT -5
IDK if it's VDEX, WDEX, XDEX or Afrezza at the local farmers market - we need some s--t to change and change soon. Unleash the Kendall, screw the FDA, where is the pediatric trial results and approval. Geezus - can we have some success while I'm still on top of the ground already. And if MC can't get the ball over the goal line - get someone who can. Sorry I went off on a rant. Please forgive me I'm cranking some MONTROSE and sipping on TITO'sI get in those moods now and then myself!  Outstanding. Might I suggest sipping on some Santo Fino tequila when cranking Montrose. 😆🥃 |
|
|
|
Post by sportsrancho on Mar 16, 2020 12:31:02 GMT -5
Vdex/Bill buys shares of MNKD at .84
$10,000+👍🏻
|
|
|
|
Post by sportsrancho on Mar 16, 2020 12:43:06 GMT -5
I was worried about the Vdex patients having to sit in a waiting room mainly because my chiropractor’s office just shut down because of the virus. His wife’s gym also closed.
Bill told me each patient is being ushered into a private room ( they have many ) so nobody is sitting around together in a lobby or room waiting for their appointment. There are also measures being taken to get them screened before they come in.
All good, full steam ahead/keeping diabetics healthy!
|
|
|
|
Post by oldfishtowner on Mar 16, 2020 12:45:25 GMT -5
Vdex/Bill buys shares of MNKD at .84 $10,000+👍🏻 I bought at $0.83 this morning. I didn't buy nearly as much as Bill because: 1. I already have enough MNKD stock for my portfolio; 2. this bear market has a ways to go; and 3. there are so many "cheap" S&P 500 stocks out there with great dividends. It's like being in a candy store.
|
|
|
|
Post by sportsrancho on Mar 20, 2020 9:41:52 GMT -5
|
|
|
|
Post by sportsrancho on Mar 20, 2020 11:25:12 GMT -5
|
|
|
|
Post by sugarland on Mar 20, 2020 12:00:11 GMT -5
I agree with his thought process. First point - insurance is number one problem. Secondly, gaining improved coverage is certainly a two way street with patient demand, patient results, and patient retention. He’s correct in saying better statistical evidence of clinical results with controlled prescription growth will change the insurance tide. Thirdly, once doctors see other colleagues getting the results and ease of coverage, then you see exponential growth. However, It takes leadership like this to hone in on a systematic approach to get the ball rolling. For those that disagree just look at the last 5 years of prescription growth and retention. I look forward to hearing more detailed VDex information and VDex results. Thank you Sports for your continued efforts of keeping us informed. Again this is the time for all believers to work together professionally to enhance the success of today’s best insulin. |
|
|
|
Post by rfogel on Mar 20, 2020 12:00:28 GMT -5
Can you offer a brief summary?
|
|
|
|
Post by mango on Mar 20, 2020 12:01:01 GMT -5
Is it just me, or does Sports keep getting younger looking in her pics?
|
|
|
|
Post by sportsrancho on Mar 20, 2020 12:31:25 GMT -5
Can you offer a brief summary? • Put all patients on who are deemed to be candidates, regardless of ability to pay • Use providers (like Vdex) who know how to get best results • Gather data to present to payers ___________________________________ A. You hear about insurance coverage as a major obstacle in getting and keeping people on Afrezza. That’s true, but strategy MNKD is following is backward: they’re saying there will be more sales with more insurance coverage; I’m saying there will be more insurance coverage when there are more sales. So, produce the sales/users with free product. Put all patients on who are deemed to be candidates. Get patients hooked, hooked on wellness. Let them pressure insurance plans. What about expense? Company is spending huge amounts on unsuccessful sales force. Use a fraction to just put patients on. B. Must have great results so only let docs use who know how to get em, like Vdex. Reduce distribution. Seems counterintuitive but bad results hurt Afrezza. Great results must be all industry sees. Use it alone – Celine Dion, Adele, Whitney Houston. C. Gather data. Vdex is doing so and already has a lot. MNKD should also do studies to highlight results. Data will prove why Afrezza expense is worth it to insurance plans so they’ll cover. [individual videos on each of three points will follow; some initial scribblings below] Show what most doctors and insurance plans don’t believe: that with Afrezza you can both bring A1c down and reduce hypos. With Afrezza you can truly control disease for the first time. No other therapeutic agent can do this. Only Afrezza and only used properly. Diabetes is the biggest disease in the world. It’s an ongoing crisis. The disease of diabetes isn’t close to being controlled, but for most patients it can be through this plan. This is why Afrezza can’t fail with this marketing plan. |
|
|
|
Post by sportsrancho on Mar 20, 2020 12:33:31 GMT -5
I agree with his thought process. First point - insurance is number one problem. Secondly, gaining improved coverage is certainly a two way street with patient demand, patient results, and patient retention. He’s correct in saying better statistical evidence of clinical results with controlled prescription growth will change the insurance tide. Thirdly, once doctors see other colleagues getting the results and ease of coverage, then you see exponential growth. However, It takes leadership like this to hone in on a systematic approach to get the ball rolling. For those that disagree just look at the last 5 years of prescription growth and retention. I look forward to hearing more detailed VDex information and VDex results. Thank you Sports for your continued efforts of keeping us informed. Again this is the time for all believers to work together professionally to enhance the success of today’s best insulin. You are so welcome, and thank you for your thoughts! |
|
|
|
Post by sportsrancho on Mar 20, 2020 12:35:15 GMT -5
Three more videos will be coming detailing the specifics.
|
|
|
|
Post by ktim on Mar 20, 2020 16:20:45 GMT -5
He cites the need to collect data that could be provided to insurance companies. Long ago I hoped VDex would help play this role.
I don't know if insurance companies would pay a lot of attention to post-hoc data analysis but it might carry some weight. Would have been nice if VDex had started an investigator initiated trial way back.
I don't know how he expects MNKD to limit the doctors that prescribe Afrezza.
|
|
|
|
Post by sugarland on Mar 20, 2020 18:21:50 GMT -5
The more prescribers the better, for sure. But I think the point he’s making is to prescribe under a more controlled protocol that works and supports reimbursement criteria versus sporadic hit and miss cases that prescribe without follow up on all clinical and insurance aspects. You identify the eligible patients based on a set of inclusion / exclusion criteria, target CGM individuals if possible, write the script, send all documented findings based on this criteria to insurance, then remain diligent with protocols throughout long term follow up. How many times have we read about someone getting coverage for a while, then it’s dropped. This is where it takes willing medical personnel and patients to continue with an aggressive approach utilizing documented protocols and results both before and after. More importantly, this is where MNKD should have detailed support systems in place to assist, and expedite. Especially considering the limited geographical areas there targeting. When a specific successful protocol is in place ( which VDEX claims), backed up with clinical data, and supported by MNKD as a whole, then the slugs on the insurance end have less wiggle room to deny or play stall tactics until the office or patient just gives up. So if VDEx can develop an efficient game plan that facilitates better coverage, or better patient compliance without coverage then I’m all ears and eyes. It sounds to me like they are just more willing to go after it, compared to your typical endo office seeing 150 people a day and letting insurance companies play doctor for you and your patients. Identify the people and practices that want better in life and focus on that core group. Get results and eventually the pot will sweeten. Just my two cents as a frustrated share holder. Be healthy
|
|
|
|
Post by ktim on Mar 20, 2020 18:53:05 GMT -5
The more prescribers the better, for sure. But I think the point he’s making is to prescribe under a more controlled protocol that works and supports reimbursement criteria versus sporadic hit and miss cases that prescribe without follow up on all clinical and insurance aspects. You identify the eligible patients based on a set of inclusion / exclusion criteria, target CGM individuals if possible, write the script, send all documented findings based on this criteria to insurance, then remain diligent with protocols throughout long term follow up. How many times have we read about someone getting coverage for a while, then it’s dropped. This is where it takes willing medical personnel and patients to continue with an aggressive approach utilizing documented protocols and results both before and after. More importantly, this is where MNKD should have detailed support systems in place to assist, and expedite. Especially considering the limited geographical areas there targeting. When a specific successful protocol is in place ( which VDEX claims), backed up with clinical data, and supported by MNKD as a whole, then the slugs on the insurance end have less wiggle room to deny or play stall tactics until the office or patient just gives up. So if VDEx can develop an efficient game plan that facilitates better coverage, or better patient compliance without coverage then I’m all ears and eyes. It sounds to me like they are just more willing to go after it, compared to your typical endo office seeing 150 people a day and letting insurance companies play doctor for you and your patients. Identify the people and practices that want better in life and focus on that core group. Get results and eventually the pot will sweeten. Just my two cents as a frustrated share holder. Be healthy MNKD has no control over the protocol that any doctors choose to use. They can, and do, offer education to clinical staff and support with insurance reimbursement, but they can't force doctors or somehow exclude other docs from using Afrezza. If it's carried at pharmacies, any doctor can prescribe. The HFM argument in this video might suggest not doing DTC marketing, but to my knowledge none is happening. |
|
